Peps
What is Eloralintide?
Eloralintide is an experimental weight-loss drug from Eli Lilly that acts on amylin receptors instead of the GLP-1 receptor used by semaglutide and tirzepatide. In a 48-week phase 2 trial, average weight loss ranged from about 9% to 20% across dose groups, versus 0.4% on placebo. It is not approved, and phase 3 trials began in 2025 and 2026.
2:45Video overview · 2:45
Eloralintide: Eli Lilly's Amylin Weight-Loss Drug, Explained (What the Trials Show)
How the amylin fullness hormone works, what the 48-week phase 2 trial found, the side effects, how it differs from cagrilintide, the phase 3 trials under way, and why it is not approved.
Narrated with an AI voice from this profile's sources; education only, no dosing. Watch on YouTube ↗
Biological role or research focus
Weight loss through the amylin (fullness) pathway.
One 48-week phase 2 trial of 263 people, run and funded by the manufacturer. It does not show effects on heart disease, long-term safety or whether the weight stays off, and it did not compare eloralintide with GLP-1 drugs or with cagrilintide. Phase 3 results are not expected until about 2028.
Names you may encounter
LY3841136 · LY-3841136
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Long-acting, once-weekly amylin receptor agonist from Eli Lilly that prefers the AMY1 receptor; not a GLP-1 drug and not approved
- Research focus
- Weight loss through the amylin (fullness) pathway
- Featured evidence
- Human randomized phase 2 trial
- Source check
- October 12, 2026
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| 48-week phase 2 trial in adults with obesity or overweight (2025) | Human randomized phase 2 trial | 263 adults aged 18 to 75 at 46 US research centers with a BMI of 30 or more, or 27 or more with at least one weight-related condition, and without type 2 diabetes. Mean body weight 109 kg; 78% women. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized phase 2 trial · 2025
48-week phase 2 trial in adults with obesity or overweight
What did this publication test, and what did it find?
- Population / model
- 263 adults aged 18 to 75 at 46 US research centers with a BMI of 30 or more, or 27 or more with at least one weight-related condition, and without type 2 diabetes. Mean body weight 109 kg; 78% women.
- Study design
- Double-blind, placebo-controlled phase 2 trial funded by Eli Lilly. Participants were randomly assigned to once-weekly injections of placebo or one of six eloralintide dose groups, including two that started lower and stepped up, for 48 weeks. The main outcome was percent change in body weight.
- Main finding
- Average weight change at 48 weeks ranged from about -9% in the lowest dose group to about -20% in the highest groups, versus -0.4% with placebo, and weight loss rose with dose. The most common side effects were nausea (11% to 64% across dose groups, versus 14% with placebo) and fatigue (0% to 46%, versus 12%); both were more common in the higher dose groups than in the lowest ones, though not in a steady pattern.
- Limits & context
- One 48-week phase 2 trial of 263 people, run and funded by the manufacturer. It does not show effects on heart disease, long-term safety or whether the weight stays off, and it did not compare eloralintide with GLP-1 drugs or with cagrilintide. Phase 3 results are not expected until about 2028.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
22 registered studies name Eloralintide as an intervention; 14 are recruiting or under way, 1 has not started recruiting yet and 7 completed. Checked October 12, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 22 listed studies.
Search additional PubMed records ↗Risks & interactions
Eloralintide is an investigational amylin-receptor drug. In trials, nausea and fatigue were the most common side effects; long-term safety and rare harms are not yet known.
Safety data come from phase 1 studies and one 48-week phase 2 trial of 263 adults, all funded by Eli Lilly. They are too small and short to rule out rare or long-term harms; phase 3 trials are under way.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Side effects reported in studies
- nausea
- fatigue
- decreased appetite
- headache
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Eloralintide phase 2 trial, 48 weeks (Lancet, 2025) ↗ · Eloralintide phase 1, 12 weeks (Diabetes Obes Metab, 2026) ↗ · Eloralintide from discovery to phase 1 (Mol Metab, 2025) ↗
Safety & what remains unknown
Nausea and fatigue were the most common side effects in phase 2, mostly in the higher dose groups. In a 12-week phase 1 study of 100 people, decreased appetite, headache and fatigue were most common, and stomach-related side effects were less frequent. Trials so far are too small and short to detect rare or long-term harms.
Evidence boundaries
One 48-week phase 2 trial of 263 people, run and funded by the manufacturer. It does not show effects on heart disease, long-term safety or whether the weight stays off, and it did not compare eloralintide with GLP-1 drugs or with cagrilintide. Phase 3 results are not expected until about 2028.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA, checked October 12, 2026). It is an investigational drug in phase 3 trials. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (checked October 12, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Other notes
- Five phase 3 trials sponsored by Eli Lilly were recruiting on ClinicalTrials.gov when checked (October 12, 2026), with primary completion dates in 2028. source
Checked October 8, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
Eloralintide is an investigational medicine being developed by Eli Lilly for obesity and weight-related conditions. Phase 3 trials started in late 2025 and 2026, including studies in obesity with and without type 2 diabetes, sleep apnea and knee osteoarthritis, and others are testing it with tirzepatide. It is not approved anywhere, and products sold online as "research" eloralintide are not the drug tested in these trials. PepsRadar does not link to sellers from this page.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. This drug is still investigational and is not approved for sale. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
Biology & proposed mechanism
Amylin is a hormone released by the pancreas with insulin after a meal; it helps signal fullness to the brain and slows stomach emptying. There are several amylin receptors (AMY1, AMY2, AMY3) plus the related calcitonin receptor. In laboratory tests, eloralintide activated the human AMY1 receptor about 12 times more strongly than the calcitonin receptor and 11 times more strongly than AMY3, while cagrilintide, another amylin drug, acts broadly across them. Natural amylin lasts only hours in the blood; eloralintide was modified to last long enough for once-weekly injection. Whether its receptor selectivity changes benefits or side effects in people has not been shown.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Questions worth asking
- Is eloralintide a GLP-1 drug?
- What material, population, and route were actually studied?
- One 48-week phase 2 trial of 263 people, run and funded by the manufacturer. It does not show effects on heart disease, long-term safety or whether the weight stays off, and it did not compare eloralintide with GLP-1 drugs or with cagrilintide. Phase 3 results are not expected until about 2028.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 29 caption files are indexed from 18,167 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Frequently asked questions
Is eloralintide a GLP-1 drug?
No. It acts on amylin receptors, a different fullness hormone pathway. That is why it is being tested both alone and together with tirzepatide, which acts on the GLP-1 and GIP receptors.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-12. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.